| Scrip Code | 524412 |
|---|---|
| NSE Symbol | AAREYDRUGS |
| MSEI Symbol | NOTLISTED |
| ISIN | INE198H01019 |
| Name of company | Aarey Drugs and Pharmaceuticals limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 14-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 07-08-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Single segment |
| Description of single segment | DRUGS AND PHARMACEUTICALS |
| Start date and time of board meeting | 14-08-2026 17:00:00 |
| End date and time of board meeting | 14-08-2026 19:00:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | Yes |
| No. of times funds raised during the quarter | 1 |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| NA | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 4,462.55 | 4,462.55 | |
| Other income | 171.50 | 171.50 | |
| Total income | 4,634.05 | 4,634.05 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 4,347.76 | 4,347.76 |
| (b) | Purchases of stock-in-trade | 0.00 | 0.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (132.35) | (132.35) |
| (d) | Employee benefit expense | 16.34 | 16.34 |
| (e) | Finance costs | 167.44 | 167.44 |
| (f) | Depreciation, depletion and amortisation expense | 85.02 | 85.02 |
| (f) | Other Expenses | ||
| 1 | General Administrative expense | 17.95 | 17.95 |
| 2 | Selling and Distribution Expense | 34.62 | 34.62 |
| 3 | other expense | 45.71 | 45.71 |
| Total other expenses | 98.28 | 98.28 | |
| Total expenses | 4,582.49 | 4,582.49 | |
| 3 | Total profit before exceptional items and tax | 51.56 | 51.56 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 51.56 | 51.56 |
| 6 | Tax expense | ||
| 7 | Current tax | 30.00 | 30.00 |
| 8 | Deferred tax | (80.81) | (80.81) |
| 9 | Total tax expenses | (50.81) | (50.81) |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 102.37 | 102.37 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 102.37 | 102.37 |
| 17 | Other comprehensive income net of taxes | 0.00 | 0.00 |
| 18 | Total Comprehensive Income for the period | 102.37 | 102.37 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 2,845.43 | 2,845.43 | |
| Face value of equity share capital | 10 | 10 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 0.36 | 0.36 | |
| Diluted earnings (loss) per share from continuing operations | 0.36 | 0.36 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 0.36 | 0.36 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 0.36 | 0.36 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | ||
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| Total Amount of items that will not be reclassified to profit and loss | |||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | ||
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | ||
| 5 | Total Other comprehensive income | ||
| Mode of Fund Raising | Preferential Issues |
|---|---|
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 23-05-2025 |
| Amount Raised | 797.50 |
| Report filed for Quarter ended | 30-06-2026 |
| Monitoring Agency | Not Applicable |
| Monitoring Agency Name, if applicable | |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | |
| If Yes, Date of shareholder Approval | |
| Explanation for the Deviation / Variation | |
| Comments of the Audit Committee after review | |
| Comments of the auditors, if any |
| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1 | The Company, as a part of its financial strategy, proposes to offer, issue and allot Convertible Warrants to its Promoter/Non-Promoter/Promoter group member on preferential basis, for infusing additional funds in the Company which may be employed in the business of the Company and/or may be used to augment the funding needs for re-structuring/settlement of liabilities/debts and/or such other appropriate arrangements and/or understanding with Bankers and/or other Creditors and/or investment in technology and/or for general corporate purposes which shall enhance the business of the Company and for any other purpose as may be decided and approved by the Board. | NA | 3,190.00 | 0.00 | 0.00 | 0.00 | The Company had allotted 50,00,000 Convertible Warrants on May 23, 2025, at an issue price of Rs. 63.80 per warrant, aggregating to Rs. 3,190.00 lakhs. In accordance with the SEBI (ICDR) Regulations, 25% of the consideration amounting to Rs. 797.50 lakhs was received at the time of allotment and was utilized for the stated objects. The balance 75% consideration amounting to Rs. 2,392.50 lakhs is receivable upon exercise/conversion of the warrants within the prescribed period. The aforesaid details were reported in the Statement of Deviation and Variation for the year ended March 31, 2026. During the quarter ended June 30, 2026, no further funds were received towards the balance consideration of the Convertible Warrants. Accordingly, there was no fresh fund receipt or utilization during the quarter and the Statement of Deviation and Variation for the quarter ended June 30, 2026 has been filed as Nil. |
| Name of signatory | Mira Ghatalia |
| Designation of person | Chief Financial Officer |
| Place | Mumbai |
| Date | 14-08-2026 |